Biologics Exclusivity: GPhA Making Last Stand Against TPP
This article was originally published in PharmAsia News
Executive Summary
The U.S. Generic Pharmaceutical Association and other groups are opposing the Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.